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Platelets are cell fragments lacking nuclei that play a key role in blood clotting. Using an 
impressive genetic screen involving ENU-mutagenesis of whole mice, Mason et al. (2007) 
report in this issue their identification of mutations in the antiapoptotic protein Bcl-xL that 
cause accelerated death of platelets leading to platelet deficiency.Although many events in the apop-
totic pathway involve the nucleus—
such as nuclear condensation, DNA 
fragmentation, and a requirement for 
new RNA synthesis—cells lacking 
nuclei, such as blood platelets, also 
undergo programmed cell death. As 
in nucleated cells, platelets possess 
Bcl-2 family proteins, which are key 
regulators of the mitochondrial death 
pathway. These include both pro-sur-
vival (Bcl-2, Bcl-xL) and proapoptotic 
(Bax, Bak) family members (Bertino 
et al., 2003). In addition, platelets 
possess other key components of the 
pathway including Apaf-1, caspase-
9, and caspase-3. However, it has 
been difficult to determine whether 
these factors have detrimental or 
beneficial effects on platelet survival 
or biogenesis. That is, do pro-death 
factors enhance platelet biogen-
esis by promoting the fragmentation 
of the platelet progenitor cell, the 
megakaryocyte, or do they promote 
platelet death, which typically occurs 
after a week in the blood stream? 
Some evidence suggests that proa-
poptotic Bax promotes production 
of platelets (Dale and Friese, 2006), 
and that overexpression of antiapop-
totic Bcl-xL impairs the fragmentation 
of megakayocytes (Kaluzhny et al., 
2002; Figure 1). These findings con-
trast with the observation that levels 
of Bcl-xL protein rapidly decline when 
platelets are stored, which suggests 
that Bcl-xL might play an important 
role in platelet survival (Bertino et al., 
2003). Furthermore, in some circum-
stances Bax can be antiapoptotic 
and Bcl-xL can be proapoptotic (Clem 
et al., 1998; Lewis et al., 1999). There-fore, it has been challenging to show 
whether endogenous Bcl-xL plays a 
critical role in platelet survival in vivo.
Huang, Kile, and colleagues now 
report that Bcl-xL and Bak regu-
late the life span of platelets in mice 
(Mason et al., 2007). These findings 
stem from a stunning effort in which 
mice were treated with the mutagen 
N-ethyl-N-nitrosourea (ENU) and 
their first generation offspring were 
screened for dominant platelet defi-
ciency (thrombocytopenia). Even in 
simpler organisms this strategy often 
entails heroic effort and has only 
rarely been accomplished in mice. 
Nevertheless, these investigators 
succeeded in identifying five heritable 
dominant mutations causing throm-
bocytopenia. Two of the five muta-
tions (Plt20 and Plt16) mapped to 
the same segment of chromosome 2. 
Further haplotype mapping of these 
mutations and subsequent sequence 
analysis revealed that each mutation 
causes a single amino acid change in 
Bcl-xL, from Tyr15 to Cys (Plt20) and 
Asn182 to Ile (Plt16).
To further explore the role of Bcl-
xL in thrombocytopenia, the authors 
examined Bcl-xL heterozygous knock-
out mice. They found that Bcl-xL het-
erozygous knockout mice, as in mice 
with either the Plt20 or the Plt16 muta-
tion, have fewer platelets than wild-
type mice, strongly indicating that 
haploinsufficiency for Bcl-xL causes 
thrombocytopenia. In contrast, plate-
let cell numbers were not affected in 
mice heterozygous for Bcl-2, Bcl-w, 
or Mcl-1, consistent with previous 
observations that Bcl-w and Mcl-1 are 
poorly expressed in human platelets Cell 128, Mand that levels of Bcl-2 expression are 
significantly lower than Bcl-xL (Zhang 
et al., 2007).
To address the role of Bcl-xL in plate-
lets in vivo, Mason et al. first analyzed 
platelet production. Bcl-xL mutant 
mice exhibited robust generation 
of megakaryocytes in bone marrow 
Figure 1. Bcl-xL Controls Platelet Life Span
The fragmentation of the cytoplasm of meg-
akaryocytes gives rise to platelets, which then 
circulate in the bloodstream, surviving for an av-
erage of 10 days. Mason et al. (2007) subjected 
mice to ENU mutagenesis and screened their 
first generation offspring for platelet deficien-
cy. They identified two mutations in the gene 
encoding the antiapoptotic factor Bcl-xL that 
give rise to a dominantly inherited reduction in 
platelet count. Further evidence indicates that 
Bcl-xL promotes platelet survival through inhibi-
tion of the proapoptotic activity of Bak. Bcl-2 
family members may also regulate platelet pro-
duction. Bax promotes production of platelets 
(Dale and Friese, 2006), and overexpression of 
antiapoptotic Bcl-xL impairs the fragmentation 
of megakayocytes (Kaluzhny et al., 2002).arch 23, 2007 ©2007 Elsevier Inc. 1035
and spleen, normal numbers of meg-
akaryocyte progenitors, and normal 
mature megakaryocyte morphology 
and ploidy profile. Only minor effects 
on platelet number were observed in 
spleens from mice homozygous for 
the Bcl-xL Plt20 mutation. Next, they 
found that platelets from Plt16, Plt20, 
or Bcl-xL heterozygous knockout mice 
had decreased half-lives and were 
cleared more quickly than wild-type 
platelets in reciprocal adoptive trans-
fer assays. In addition, the average 
age of platelets from Bcl-xL Plt20, and 
Plt16 mice is younger than in wild-
type mice, consistent with selective 
loss of older platelets. Together, the 
evidence suggests that Bcl-xL defi-
ciency directly reduces platelet life 
span but does not impair platelet 
production.
They then sought to understand 
the molecular mechanisms by which 
Bcl-xL lengthens the life span of 
platelets. Both the Plt16 and Plt20 
Bcl-xL mutant proteins fully retain 
their ability to interact with proapop-
totic proteins Bak and Bax. However, 
both mutant proteins are less stable 
and are degraded more quickly than 
wild-type Bcl-xL. In mouse embryonic 
fibroblasts from Plt16 homozygous 
mice, the basal level of endogenous 
Bcl-xL was decreased. Consistent 
with the model that these mutations in 
Bcl-xL destabilize the protein, mouse 
embryonic fibroblasts derived from 
Plt20 or Plt16 homozygous mice were 
more sensitive than wild-type cells to 
cell death induced when new protein 
synthesis was inhibited by cyclohex-
imide but not by other damaging sig-
nals such as staurosporine.
An alternative pharmacologic 
approach was undertaken to dem-
onstrate the importance of Bcl-xL in 1036 Cell 128, March 23, 2007 ©2007 Elplatelet survival. The small molecule 
ABT-737, designed to mimic the BH3 
domain of proapoptotic Bcl-2 family 
proteins by inserting into the cleft on 
Bcl-xL, rapidly induced thrombocy-
topenia in mice (Mason et al., 2007) 
and in dogs (Zhang et al., 2007). 
This thrombocytopenia was at least 
partially dependent on caspases 
(Mason et al., 2007). Younger plate-
lets were highly resistant to ABT-737 
treatment, whereas older platelets 
were more susceptible, as would be 
expected given that younger plate-
lets contain more Bcl-xL protein that 
is gradually lost with platelet aging. 
Therefore, the amount of Bcl-xL may 
act as a type of molecular clock 
(Mason et al., 2007). Although ABT-
737 is proposed to prevent Bcl-xL 
from binding and inhibiting Bax or 
Bak, it remains possible that ABT-
737 converts Bcl-xL into a pro-death 
factor that subsequently cooperates 
with Bax or Bak.
To determine if Bax or Bak is the 
key mediator of platelet cell death 
and thrombocytopenia in vivo, Mason 
et al. examined the effects of Bax and 
Bak deficiency. Bak knockout, but not 
Bax knockout, mice exhibited defects 
in platelet homeostasis and had sig-
nificantly higher platelet counts and 
prolonged platelet half-life compared 
to wild-type mice. More importantly, 
the absence of Bak reversed the 
thrombocytopenia of Plt16 or Plt20 
mutants, and Bcl-xL heterozygous 
knockout mice, indicating that Bak is 
the critical killer of platelets.
Genome-wide, phenotype-driven 
mutagenesis screens to identify dom-
inant mutations were only recently 
developed for mice (Hrabe de Ange-
lis et al., 2000) and have been used 
to identify only a few genes. However, sevier Inc.recent advances in technology make 
it feasible to detect single point muta-
tions in the entire yeast genome or in 
human chromosomes using a sin-
gle DNA tiling array (Gresham et al., 
2006). These and other developing 
technologies, including rapid rese-
quencing of entire genomes, have 
enormous potential for revealing the 
functions of mammalian genes and 
may soon make phenotype-driven 
mutagenesis screens, exemplified 
by the heroic efforts of Mason et al., 
more commonplace.
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